Midatech Pharma PLC Directorate Change (5467P)
June 20 2022 - 12:58PM
UK Regulatory
TIDMMTPH
RNS Number : 5467P
Midatech Pharma PLC
20 June 2022
20 June 2022
Midatech Pharma PLC
("Midatech" or the "Company")
Directorate Change
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), an R&D
biotechnology company focused on improving the bio-delivery and
biodistribution of medicines , is pleased to announce the
appointment of Dr Stephen Parker as a Director of the Company and
Non-Executive Chairman of the Board with immediate effect.
Stephen Parker has over 30 years' experience in leadership roles
both in the healthcare industry and in advisory roles. Currently,
he is Chairman of Sareum Holdings plc (AIM: SAR) and Drishti
Discoveries Ltd., a Non-Executive Director of MGC Pharmaceuticals
Ltd (ASX,LSE: MXC) and an Executive Director of sp(2) Consulting
Limited. Previously, Stephen held a number of executive and board
positions at various public and private biotech companies and
senior roles at leading investment banks. Stephen has an MBA from
City University and a D.Phil. in biochemistry from Oxford
University.
Dr Parker is taking over from Rolf Stahel, who has resigned as a
Director of the Company and stepped down as Chairman in line with
his proposed retirement, previously announced on 10 June 2022.
Additional Information
The following information is disclosed pursuant to Schedule Two
paragraph (g)of the AIM Rules for Companies in relation to Dr
Stephen Barry Parker, aged 63:
Current Directorships and Partnerships Previous Directorships and Partnerships
(past 5 years)
Sareum Holdings Plc Silence Therapeutics Plc
----------------------------------------
Sareum Limited Liverpool Chirochem Limited
----------------------------------------
sp(2) Consulting Limited Albucasis Limited
----------------------------------------
sp(2) Asset Management Ltd
----------------------------------------
MGC Pharmaceuticals Limited
----------------------------------------
Drishti Discoveries Ltd.
----------------------------------------
Eternans Ltd
----------------------------------------
Dr Parker was formerly a director of Celtic Pharma Development
UK Plc, Xenova Group Limited and Xenova Limited, each of which were
subsidiaries of Celtic Pharma GP Limited and were placed into
creditors voluntary liquidation in April 2014.
As of the date of this announcement, Dr Parker holds no ordinary
shares or options in the Company.
Save as disclosed above, there are no additional disclosures to
be made in accordance with Schedule Two paragraph (g) of the AIM
Rules for Companies.
For more information, please contact:
Midatech Pharma PLC
Stephen Parker, Chairman
Stephen Stamp, CEO, CFO
Tel: +44 (0)29 20480 180
www.midatechpharma.com
Strand Hanson Limited (Nominated and Financial Adviser)
James Dance / Matthew Chandler / Rob Patrick
Tel: +44 (0)20 7409 3494
Turner Pope Investments (TPI) Ltd (Joint Broker)
Andrew Thacker / James Pope
Tel: +44 (0)20 3657 0050
IFC Advisory Limited (Financial PR and UK Investor Relations)
Tim Metcalfe / Graham Herring
Tel: +44 (0)20 3934 6630
Email: midatech@investor-focus.co.uk
Edison Group (US Investor Relations)
Alyssa Factor
Tel: +1 (860) 573 9637
Email: afactor@edisongroup.com
About Midatech Pharma PLC
Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ:
MTP) is a drug delivery technology company focused on improving
the bio-delivery and bio-distribution of medicines . The Company
combines approved and development medications with its proprietary
and innovative drug delivery technologies, to provide compelling
products that have the potential to powerfully impact the
lives of patients.
The Company has developed three in-house technology platforms,
each with its own unique mechanism to improve delivery of
medications to sites of disease. All of the Company's technologies
have successfully entered human use in the clinic, providing
important validation of the potential for each platform:
* Q-Sphera(TM) platform: a disruptive micro-technology
used for sustained release to prolong and control the
release of therapeutics over an extended period of
time (from weeks to months).
* MidaSolve(TM) platform: an innovative nanotechnology
used to dissolve insoluble drugs so that they can be
administered in liquid form directly and locally into
tumours.
* MidaCore(TM) platform: a leading-edge nanotechnology
used for targeting medications to sites of disease.
The platform nature of the technologies offers the potential
to develop multiple drug assets rather than being reliant
on a limited number of programmes. Midatech's technologies
are supported by 36 patent families including 120 granted
patents and an additional 70 patent applications. Midatech's
headquarters and R&D facility is in Cardiff, UK. For more
information, please visit www.midatechpharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAKZGZVVGNGZZM
(END) Dow Jones Newswires
June 20, 2022 12:58 ET (16:58 GMT)
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Midatech Pharma (LSE:MTPH)
Historical Stock Chart
From Apr 2023 to Apr 2024
